Neurodegenerative diseases

This page brings together the European Medicines Agency's (EMA) latest information on diseases causing problems with the brain and nervous system, including Alzheimer's disease, Parkinson's disease and multiple sclerosis.

 It lists the following:

• The newest and most recently updated medicines authorised for the treatment of neurodegenerative diseases in the European Union
• EMA's latest news announcements related to neurodegenerative diseases
• EMA's events on topics related to neurodegenerative diseases

We are currently unable to display the new and recently updated medicines authorised for neurodegenerative diseases due to a technical error. We are working to resolve the issue as soon as possible. We apologise for any inconvenience caused.

Latest news

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 March 2024

EMA’s human medicines committee (CHMP) recommended 12 medicines for approval at its March 2024 meeting.

22 maart 2024

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 February 2024

EMA’s human medicines committee (CHMP) recommended 10 medicines for approval at its February 2024 meeting.

23 februari 2024

New treatment for rare motor neurone disease recommended for approval

EMA has recommended granting a marketing authorisation in the European Union for a new therapy for the treatment of adult patients with amyotrophic lateral sclerosis (ALS), a rare and often fatal disease that causes muscles to become weak and leads to paralysis. Qalsody (tofersen) is indicated for the treatment of adults with ALS, who have a...

23 februari 2024

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 December 2023

EMA’s human medicines committee (CHMP) recommended seven medicines for approval at its December 2023 meeting.

15 december 2023

SEE ALL NEWS

Events of interest

Currently, we have no events for this therapeutic area.